Graft-versus-Host-Disease (GvHD) is a common complication of stem cell transplantation that is associated with high morbidity and mortality. Our goal is to prevent the development of GvHD at an early stage with the cellular therapy ATreg and thus to provide a curative therapy with few side effects for patients with blood stem cell transplantation for the first time. ATreg is a safe and efficient treatment option for transplanted patients providing substantial improvement of survival rate and quality of life. ATreg addresses a high unmet medical need and has the potential to solve the current risks and limitations inherent with stem cell transplantation.
GvHD is a life-threatening side effect of stem cell transplantation. Donor lymphocytes react against tissue antigens in the recipient and cause severe organ and tissue damage, that often takes a chronic course. GvHD is primarily triggered by the donor's CD4+ T lymphocytes, immune cells whose activity is controlled by regulatory T cells. More than 50% of patients develop the disease with a mortality rate of 20%. Once developed, patients suffer from the often life-long symptoms.
ATreg is a cellular therapeutic agent that contains optimally activated regulatory T cells, the natural guardian cells of our immune system. Regulatory T cells modulate the activity of T lymphocytes and prevent unwanted inflammatory reactions. ATreg suppresses the undesired activation of CD4+ T lymphocytes in the transplant, prevents the development of GvHD and promotes the development of a healthy immune system in the patient.
The cellular therapeutic ATreg is classified as an Advanced Therapy Medicinal Product (ATMP), produced in an automated process within 24 hours and ready for clinical use in patients.
ActiTrexx is sponsored by a grant from the German Ministry of Education and Research
Activated regulatory T cells - tolerance induction for therapy of transplant rejection (GvHD)
Support code: 161B0796
ActiTrexx is sponsored by the Innovationsfonds Rheinland-Pfalz II